Abstract: Compounds of the formula ##STR1## in which Y is ##STR2## X is O or S; Z is --CHOH--CH.sub.2 --CHOH--CH.sub.2 --COOH, an ester or salt thereof or the lactone thereof; andeach of R.sup.1 R.sup.2 and R.sup.3 can be alkyl, cycloalkyl; or substituted or unsubstituted phenyl; and additionally R.sup.3 can be hydrogen, are obtained by a multi-step process and are useful in the treatment of atherosclerosis, e.g. sodium (E)-7-(4-phenyl-2-isopropyl-5-phenylthien-3-yl)-3,5-dihydroxyhept-6-enoate .

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl or t-butyl, R.sub.2 is hydrogen or C.sub.1-3 alkyl,R.sub.3 is hydrogen or C.sub.1-3 alkyl,R.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl or t-butyl,R.sub.5 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, fluoro, chloro, trifluoromethyl, phenoxy or benzyloxy,R.sub.6 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, fluoro, chloro, trifluoromethyl, phenoxy or benzyloxy, with the provisos that not more than one of R.sub.5 and R.sub.6 is trifluoromethyl, not more than one of R.sub.5 and R.sub.6 is phenoxy, and not more than one of R.sub.5 and R.sub.6 is benzyloxy, orR.sub.5 and R.sub.6 are attached to adjacent carbon atoms and taken together form a radical of the formula --CH.dbd.CH--CH.dbd.CH--,R.sub.6a is hydrogen, C.sub.1-2 alkyl, fluoro or chloro,X is --CH.sub.2 CH.sub.2 -- or ##STR2## wherein R.sub.7 is hydrogen or C.sub.1-3 alkyl, andR.sub.8 is hydrogen, R.

Abstract: Compounds of the formula ##STR1## in which Y is ##STR2## X is O or S; Z is --CHOH--CH.sub.2 --CHOH--CH.sub.2 --COOH, an ester or salt thereof or the lactone thereof; andeach of R.sup.1, R.sup.2 and R.sup.3 can be alkyl, cycloalkyl; or substituted or unsubstituted phenyl; and additionally R.sup.3 can be hydrogen, are obtained by a multi-step process and are useful in the treatment of atherosclerosis, e.g. sodium(E)-7-(4-phenyl-2-isopropyl-5-phenylthien-3-yl)-3,5-dihydroxyhept-6- enoate.

Abstract: Compounds of the formula I: ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 is, independently, (a) alkyl having from 1 to 22 carbon atoms; or(b) of the formula ##STR2## in which m is 0, 1 or 2, and each of R' and R" is independently a hydrogen atom, alkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, or halo having an atomic weight of from about 19 to 127; and R is of an aralkyl-, phenyl- tryptophanyl- or benzocycloalkyl-type, are obtained by hydrogenating corresponding .alpha.-.beta. ethylenically-unsaturated analogs (II), which in turn are obtained by hydrogenating corresponding .alpha.-.beta. acetylenically-unsaturated analogs. Compounds I and II are useful as anti-atheroslerotic agents.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are alkyl or aryl groups, A, B, C and D are non-reactive substituents or two are joined to form an additional ring, and Z is either of the formula Z': ##STR2## wherein R.sup.4 is H, lower alkyl or a cation; or a -6-oxotetrahydropyran-2-yl ring of the formula Z": ##STR3## e.g. 4-hydroxy-6-{2-[2-(methyldiphenylsilyl)phenyl]ethenyl]ethyenyl}-tetrahydro -2H-pyran-2-one, (trans, trans). The compounds inhibit cholesterol biosynthesis and are useful as anti-atherosclerotic agents.

Abstract: Compounds of the formula I: ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 is, independently, (a) alkyl having from 1 to 22 carbon atoms; or(b) of the formula ##STR2## in which m is 0, 1 or 2, and each R' and R" is independently a hydrogen atom, alkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, or halo having an atomic weight of from about 19 to 127; and R is of an aralkyl-, phenyl- tryptophanyl- or benzo-cycloalkyl-type, are obtained by hydrogenating corresponding .alpha.-.beta. ethylenically-unsaturated analogs (II), which in turn are obtained by hydrogenating corresponding .alpha.-.beta. acetylenically-unsaturated analogs. Compounds I and II are useful as anti-atheroslerotic agents.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof, whereinR.sub.1 is C.sub.1-4 alkyl,R.sub.2 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, trifluoromethyl, C.sub.1-4 alkylthio or --NR.sub.5 R.sub.6, wherein each of R.sub.5 and R.sub.6 is independently hydrogen or C.sub.1-3 alkyl,R.sub.3 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, halo or trifluoromethyl, andR.sub.4 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy or halo,their use as muscle relaxants and as anti-inflammatory agents, pharmaceutical compositions comprising them, processes for their synthesis and compounds of the formulae ##STR2## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined above, useful as intermediates in their synthesis.

Abstract: Anti-atherosclerotic agents of the formula: ##STR1## wherein R.sup.1 is (a) alkyl having from 1 to 22 carbon atoms; or(b) of the formula ##STR2## in which m is 0, 1 or 2, and each of R' and R" is, independently, hydrogen, halo or lower alkyl or alkoxy; R.sup.2 and R.sup.3 are joined to form with the silicon atom a heterocyclic ring having from 3 to 20 ring members; and R is an aralkyl-, phenyl- tryptophanyl- or benzocycloalkyl-type radical, eg 1-butyl-N-[(2-(4'-methyl-phenyl)-1-phenylethyl]-1-silacyclohexane propanamide, are obtained by reducing corresponding .alpha.,.beta.-unsaturated analogs.